中药联合熊去氧胆酸治疗原发性胆汁性肝硬化疗效观察

目的:观察中药复方联合熊去氧胆酸(UDCA)治疗原发性胆汁性肝硬化(PBC)的临床疗效,以明确中药治疗PBC的优势所在并观察其可能存在的不良反应。方法:回顾性分析2010年5月-2013年5月在我院住院的代偿期PBC患者,符合纳入标准者共72人,根据治疗方案不同,分为治疗组(中药复方联合UDCA)35人,对照组(UDCA)37人,观察疗程为24周,观察两组患者治疗后疾病疗效、中医症状好转率及改善情况、肝功能的变化情况。结果:治疗24周后,中药组的治疗好转率显著优于对照组(P<0.05),中医症状改善率显著优于对照组(P<0.05),治疗组在改善患者倦怠乏力、食欲不振、皮肤瘙痒、口干、身目黄染、胸胁胀满方面优于对照组(P<0.05);肝功能总胆红素(TBil)、碱性磷酸酶(ALP)、γ-谷氨酰转肽酶(γ-GT)等三项指标均较对照组有显著下降(P<0.05)。结论:中药复方联合UDCA治疗PBC在提高疗效、改善症状及肝功能方面优于单用UDCA,有进一步研究的价值。

Efficacy observation of traditional Chinese medicine combined with ursode- oxycholic acid in the treatment of primary biliary cirrhosis

Objective： To observe the clinical efficacy of traditional Chinese medicine combined with ursodeoxycholic acid in treatment of primary biliary cirrhosis, so that the advantages of TCM in treatment of PBC can be cleared as well as the possible adverse reaction. Methods： Restrospective analysis of the in-patients during May 2010 to May 2013 in our hospital who were diagonosed with compensated PBC, there were 72 patients who meet the the inclusion criteria. According the different treatment, patients were divided into two groups. One group 35 cases was traditional Chinese medcine group which include traditional Chinese herbs and UDCA, the other group 37 cases was control group which include UDCA only based on the foundation treatment. The observative duration was 24 weeks. Evaluation index included clinical efficacy , improvement of TCM symptoms and changes of liver function. Results： After treatment of 24 weeks, clininal efficacy in TCM group were improved more significantly than the control group （P 〈 0. 05）, the rates of TCM symptoms improvement were higer in TCM group （ P 〈 0. 05 ）, symptoms such as fatigue, anorexia, dry mouth, pruritus, jaundice, fullness in chest and hypochondrium were improved better in TCM group than the control group （P 〈0. 05） . Furthermore, the three biochemical index of TBil, ALP and γ-GT decresed more significantly than the control group. Conclusion： Traditional Chinese medicine has some potential in the treatment of primary biliary cirrhosis when combined with UDCA, especially in improving the clinical efficacy, the TCM symptoms and liver function, so it has the value of further study.